Microsomal triglyceride transfer protein
First Claim
1. A method for treating atherosclerosis in a mammalian species comprising administration of a therapeutically effective amount of an agent which decreases the amount or activity of microsomal triglyceride transfer protein, wherein said agent is not a polynucleotide compound.
3 Assignments
0 Petitions
Accused Products
Abstract
Nucleic acid sequences, particularly DNA sequences, coding for all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials. The invention also concerns polypeptide molecules comprising all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, and methods for producing these polypeptide molecules. The invention additionally concerns novel methods for preventing, stabilizing or causing regression of atherosclerosis and therapeutic agents having such activity. The invention concerns further novel methods for lowering serum liquid levels and therapeutic agents having such activity.
-
Citations
10 Claims
- 1. A method for treating atherosclerosis in a mammalian species comprising administration of a therapeutically effective amount of an agent which decreases the amount or activity of microsomal triglyceride transfer protein, wherein said agent is not a polynucleotide compound.
-
2. A method for decreasing serum lipid levels in a mammalian species, which comprises administration of a therapeutically effective amount of an agent which decreases the amount or activity of microsomal triglyceride transfer protein, wherein said agent is not a polynucleotide compound.
-
6. A method for treating hyperglycemia in a mammalian species comprising administration of a therapeutically effective amount of an agent which decreases the amount or activity of microsomal triglyceride transfer protein, wherein said agent is not a polynucleotide compound.
-
7. A method for treating hypertriglyceridemia in a mammalian species comprising administration of a therapeutically effective amount of an agent which decreases the amount or activity of microsomal triglyceride transfer protein, wherein said agent is not a polynucleotide compound.
-
8. A method for treating hypercholesterolemia in a mammalian species comprising administration of a therapeutically effective amount of an agent which decreases the amount or activity of microsomal triglyceride transfer protein, wherein said agent is not a polynucleotide compound.
-
9. A method for treating hypertriglyceridemia and hypercholesterolemia in a mammalin species comprising administration of a therapeutically effective amount of an agent which decreases the amount or activity of microsomal triglyceride protein, wherein said agent is not a polynucleotide compound.
-
10. A method of reducing gastrointestinal triglyceride, fatty acid cholesterol absorption in a mammalian species comprising administration of a therapeutically effective amount of an agent which decreases the amount or activity of microsomal triglyceride transfer protein, wherein said agent is not a polynucleotide compound.
Specification